Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.

Simple Summary: Targeted therapy has significantly improved outcomes for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC); however, the emergence of resistance remains an inevitable clinical challenge. Standard treatment after progression on third-generation...

Full description

Bibliographic Details

Published in:	Current Oncology Vol. 33; no. 5; pp. 258 - 268
Main Authors:	Ding, Lu, Nuersulitan, Reyizha, Wang, Jingjing, Chen, Hanxiao, Zhuo, Minglei
Format:	Journal Article
Published:	MDPI May2026
Online Access:	View this record in EBSCOhost